Motixafortide TFA is primarily used in hematopoietic stem cell transplantation, particularly for patients with multiple myeloma. It functions as a CXCR4 antagonist, mobilizing stem cells from the bone marrow into the bloodstream, making them easier to collect for autologous transplantation. This enhances the efficiency of stem cell collection, especially in patients who are poor mobilizers with standard therapies like G-CSF. Its use can reduce the number of apheresis sessions needed, shortening the overall treatment timeline. Additionally, motixafortide TFA is being explored in combination with immune cell therapies to improve the homing and engraftment of therapeutic cells.